Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 4Urinary Bladder Neoplasms 2Uterine Cervical Neoplasms 1Smoking Cessation 1Prostatic Hyperplasia 1Papillomavirus Infections 1Non-melanomatous Skin Cancer 1Lung Neoplasms 1Colonic Neoplasms 1Carcinoma, Intraductal, Noninfiltrating 1Breast Neoplasms 1

Interventions

Gemcitabine 83Cisplatin 59pembrolizumab 28Paclitaxel 21Nivolumab 21Carboplatin 21Cystectomy 20Docetaxel 18durvalumab 17atezolizumab 17Magnetic Resonance Spectroscopy 16Specimen Handling 15Radiotherapy 14avelumab 13Mitomycin 13Sunitinib 12Doxorubicin 12Methotrexate 11Fluorouracil 11Vinblastine 10Filgrastim 7BCG Vaccine 7Sorafenib 6Ipilimumab 6Immunoglobulin G 6Disulfides 6Biopsy 6enfortumab vedotin 5cabozantinib 5Trastuzumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Urinary Bladder Neoplasms × polyphenon E × Clear all
NCT00088946 2020-07-31

Erlotinib and Green Tea Extract (Polyphenon® E) in Preventing Cancer Recurrence in Former Smokers Who Have Undergone Surgery for Bladder Cancer

Jonsson Comprehensive Cancer Center

Phase 2 Completed
17 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT00666562 2017-11-17

Green Tea Extract in Treating Patients With Nonmetastatic Bladder Cancer

National Cancer Institute (NCI)

Phase 2 Completed
31 enrolled 21 charts
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡